NovoCure (NVCR) Cash & Equivalents Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.15% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 24.05% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -7.50% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 100.41% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -22.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 20.15% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 23.57% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -7.71% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 156.03% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -31.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.23% |
| Dec 31, 2025 | -42.88% |
| Sep 30, 2025 | 84.51% |
| Jun 30, 2025 | -9.21% |
| Mar 31, 2025 | -71.95% |
| Dec 31, 2024 | -32.00% |
| Sep 30, 2024 | 19.74% |
| Jun 30, 2024 | 4.98% |
| Mar 31, 2024 | 144.01% |
| Dec 31, 2023 | 108.82% |
| Sep 30, 2023 | -36.48% |
| Jun 30, 2023 | -57.23% |
| Mar 31, 2023 | -2.50% |
| Dec 31, 2022 | -44.77% |
| Sep 30, 2022 | -64.66% |
| Jun 30, 2022 | 5.12% |
| Mar 31, 2022 | -39.36% |
| Dec 31, 2021 | -11.02% |
| Sep 30, 2021 | 194.22% |
| Jun 30, 2021 | 77.41% |
| Mar 31, 2021 | 72.90% |
| Dec 31, 2020 | 32.34% |
| Sep 30, 2020 | 12.70% |
| Jun 30, 2020 | 9.28% |
| Mar 31, 2020 | 19.63% |
| Dec 31, 2019 | 26.10% |
| Sep 30, 2019 | 69.19% |
| Jun 30, 2019 | 57.33% |
| Mar 31, 2019 | 36.26% |
| Dec 31, 2018 | 78.93% |
| Sep 30, 2018 | 49.76% |
| Jun 30, 2018 | 42.73% |
| Mar 31, 2018 | 31.94% |
| Dec 31, 2017 | -21.23% |
| Sep 30, 2017 | -29.11% |
| Jun 30, 2017 | -0.84% |
| Mar 31, 2017 | -27.04% |
| Dec 31, 2016 | -16.45% |
| Sep 30, 2016 | 4.98% |
| Jun 30, 2016 | -24.07% |
| Mar 31, 2016 | 56.20% |
| Dec 31, 2015 | 107.28% |
| Sep 30, 2015 | 37.94% |